Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) Given Average Recommendation of “Moderate Buy” by Brokerages

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) has received an average rating of “Moderate Buy” from the five ratings firms that are covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating and four have given a buy rating to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $20.00.

Several research analysts recently issued reports on NBTX shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Nanobiotix in a research report on Thursday, January 22nd. Guggenheim lifted their price objective on Nanobiotix from $8.00 to $26.00 and gave the company a “buy” rating in a report on Friday, February 6th. Finally, TD Cowen reiterated a “buy” rating on shares of Nanobiotix in a research note on Thursday, March 12th.

Nanobiotix Price Performance

NBTX opened at $29.95 on Monday. The business has a 50 day moving average of $27.23 and a 200-day moving average of $22.83. Nanobiotix has a 1-year low of $2.99 and a 1-year high of $41.89.

Hedge Funds Weigh In On Nanobiotix

Several institutional investors have recently bought and sold shares of NBTX. Millennium Management LLC bought a new stake in shares of Nanobiotix during the fourth quarter valued at approximately $390,000. Royal Bank of Canada raised its position in Nanobiotix by 2,000.0% in the 4th quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock worth $61,000 after purchasing an additional 2,500 shares during the last quarter. Marshall Wace LLP bought a new position in Nanobiotix in the 4th quarter worth approximately $220,000. Finally, Optiver Holding B.V. acquired a new position in Nanobiotix during the 3rd quarter worth $101,000. Institutional investors own 38.81% of the company’s stock.

Nanobiotix Company Profile

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.